The Indian Pharmaceutical Association (IPA) is organizing its third convention in Mumbai from September 14 to 16, 2003. The theme of the convention is “Destination India-Global Pharma Business”. The objective of the convention is to project India as a manufacturing centre for quality APIs and pharmaceutical products. The two-day conference and exhibition are expected to provide a comprehensive picture of India’s capabilities and potential.
Nearly 300 participants from all over India and 200 from abroad are expected to participate in the convention. Dr.Vinod Shah, president of American Association Pharmaceutical Sciences will speak on “cGMP for the 21st Century” during this event.
The conference sessions will be preceded by a pre-convention on Sept 14 on ICH-Q7A guidelines issued in August 2001. The intense one-day pre convention will explain the guidelines, outline specifically what is expected from manufacturers and present pragmatic ideas for ICH-Q7A implementation.
PROGRAMME
Date: 14th September 2003 : Pre - convention
Date: 15th September 2003 : Regulated Market
Date: 16th September 2003 : Non Regulated Market
DAY ONE : Regulated Market
Morning Session
| Session No. | Time | Topic | Speaker |
| | 8.45 - 9.15 | Registration | |
| Session 1 | 9.15 - 10.15 | Techno-commercial strategy for marketing in developed countries | Mr. Gautam Kumra Principal,
McKinsey & Company, INDIA |
| Session 2 | 10.15 - 11.15 | cGMPs for 21st century | Dr. Vinod Shah
President,
American Association of Pharmaceuticals Scientists (AAPS), USA |
| | 11.15 - 11.30 | Tea break | |
| Session 3 | 11.30 - 12.30 | Advancement in Pharmaceutical Technology | Mr. Hari Fluora President ,
Applied Containment Engineering, Inc., USA |
| | 12.30 - 1.30 | Lunch break | |
Afternoon Session
| Session 4 | 1.30 - 2.30 | India - An Emerging Pharmaceutical Powerhouse | Dr. Ajit Dangi
Director General,
Organisation of Pharmaceutical Producers of India (OPPI), INDIA |
| Session 5 | 2.30 - 3.15 | Opportunities - Target India | Dr. Denis Croisat
Director, API outsourcing,
Aventis Pharma, GERMANY |
| | 3.15 - 3.30 | Tea break | |
| Session 6 | 3.30 - 4.15 | Clinical Trials : Opportunities in clinical research and contract research in India | Dr Mohan Beltangdy Vice President,
Pfizer Global Research,
Pfizer Inc., USA |
DAY TWO : Non Regulated Market
Morning Session
| Session No. | Time | Topic | Speaker |
| Session 1 | 9.30 - 10.30 | Strategy for International markets : Business potential, Barriers and challenges | Mr. D. S. Brar
Managing Director,
Ranbaxy Laboratories Ltd.,
INDIA |
| Session 2 | 10.30 - 11.15 | "Global" Indian Pharmaceutical Company - a success story | Dr. Rajendra Agarwal
Managing Director,
Mcleods Pharmaceuticals Ltd., INDIA |
| | 11.15 - 11.30 | Tea break | |
| Session 3 | 11.30 - 12.30 | Sourcing APIs from India - Opportunities and challenges | Mr. Venkat Jasti
Managing Director,
Suven Pharmaceuticals Ltd.,
INDIA |
| | 12.30 - 1.30 | Lunch break | |
Afternoon Session
| Session 4 | 1.30 - 2.30 | Intellectual Property Rights : Challenges and Opportunities | Mr. Divaakar
Managing Director,
Ace Global, INDIA |
| Session 5 | 2.30 - 3.30 | Counterfeiting - International perspective | Dr. Michael Anisfeld
Globepharm, USA |
| | 3.30 - 3.45 | Tea break | |
| Session 6 | 3.45 - 4.45 | Panel Discussion
India Inc. SWOT analysis | Mr. Ashwini Kumar
Mr. Ajit Singh
Mr. D. G. Shah |
For Registration etc. contact : ipaconvention@ipaconvention.com